

UC Irvine

UC Irvine Previously Published Works

Title

Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.

Permalink

<https://escholarship.org/uc/item/7061v4r4>

Journal

European heart journal, 39(17)

ISSN

0195-668X

Authors

Kovesdy, Csaba P
Matsushita, Kunihiro
Sang, Yingying
[et al.](#)

Publication Date

2018-05-01

DOI

10.1093/eurheartj/ehy100

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis

Csaba P. Kovesdy^{1,2}, Kunihiro Matsushita³, Yingying Sang³, Nigel J. Brunskill^{4,5}, Juan J. Carrero⁶, Gabriel Chodick^{7,8}, Takeshi Hasegawa^{9,10,11,12}, Hiddo L. Heerspink¹³, Atsushi Hirayama¹⁴, Gijs W.D. Landman¹⁵, Adeera Levin^{16,17}, Dorothea Nitsch¹⁸, David C. Wheeler¹⁹, Josef Coresh^{3*}, Stein I. Hallan^{20,21}, Varda Shalev^{7,8}, and Morgan E. Grams³, for the CKD Prognosis Consortium

¹University of Tennessee Health Science Center, Memphis, TN, USA; ²Memphis Veterans Affairs Medical Center, Memphis, TN, USA; ³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Baltimore, MD 21205, USA; ⁴Department of Infection Immunity and Inflammation, University of Leicester, Leicester, UK; ⁵John Walls Renal Unit, University Hospitals of Leicester, Leicester, UK; ⁶Department of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet, Stockholm, Sweden; ⁷Medical Division, Maccabi Healthcare Services, Tel Aviv, Israel; ⁸Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ⁹Showa University, Office for Promoting Medical Research, Tokyo, Japan; ¹⁰Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan; ¹¹Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima, Japan; ¹²Department of Healthcare Epidemiology, Kyoto University Graduate School of Public Health, Kyoto, Japan; ¹³Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands; ¹⁴Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan; ¹⁵Diabetes Centre Zwolle, Isala hospital, Zwolle, The Netherlands; ¹⁶BC Provincial Renal Agency, Vancouver, BC, Canada; ¹⁷University of British Columbia, Vancouver, BC, Canada; ¹⁸Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK; ¹⁹Centre for Nephrology, University College London, London, UK; ²⁰Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science Technology, Trondheim, Norway; and ²¹Division of Nephrology, Department of Medicine, St Olav University Hospital, Trondheim, Norway

Received 11 August 2017; revised 22 November 2017; editorial decision 14 February 2018; accepted 14 February 2018; online publish-ahead-of-print 14 March 2018

See page 1543 for the editorial comment on this article (doi: 10.1093/eurheartj/ehy159)

Aims

Both hypo- and hyperkalaemia can have immediate deleterious physiological effects, and less is known about long-term risks. The objective was to determine the risks of all-cause mortality, cardiovascular mortality, and end-stage renal disease associated with potassium levels across the range of kidney function and evaluate for consistency across cohorts in a global consortium.

Methods and results

We performed an individual-level data meta-analysis of 27 international cohorts [10 general population, 7 high cardiovascular risk, and 10 chronic kidney disease (CKD)] in the CKD Prognosis Consortium. We used Cox regression followed by random-effects meta-analysis to assess the relationship between baseline potassium and adverse outcomes, adjusted for demographic and clinical characteristics, overall and across strata of estimated glomerular filtration rate (eGFR) and albuminuria. We included 1 217 986 participants followed up for a mean of 6.9 years. The average age was 55 ± 16 years, average eGFR was 83 ± 23 mL/min/1.73 m², and 17% had moderate- to-severe increased albuminuria levels. The mean baseline potassium was 4.2 ± 0.4 mmol/L. The risk of serum potassium of >5.5 mmol/L was related to lower eGFR and higher albuminuria. The risk relationship between potassium levels and adverse outcomes was U-shaped, with the lowest risk at serum potassium of 4–4.5 mmol/L. Compared with a reference of 4.2 mmol/L, the adjusted hazard ratio for all-cause mortality was 1.22 [95% confidence interval (CI) 1.15–1.29] at 5.5 mmol/L and 1.49 (95% CI 1.26–1.76) at 3.0 mmol/L. Risks were similar by eGFR, albuminuria, renin–angiotensin–aldosterone system inhibitor use, and across cohorts.

Conclusions

Outpatient potassium levels both above and below the normal range are consistently associated with adverse outcomes, with similar risk relationships across eGFR and albuminuria.

Keywords

Potassium • Estimated glomerular filtration rate • Albuminuria • End-stage renal disease • Mortality

* Corresponding author. Tel: +1 410 955 9917, Fax: +1 410-367-2384, Email: ckdpc@jhmi.edu

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.

Introduction

Abnormal serum potassium levels represent one of the most important electrolyte disturbances in clinical practice. Potassium plays a crucial role in normal cell membrane electrophysiology, with both hyperkalaemia and hypokalaemia resulting in electrophysiological perturbations, most importantly in the cardiac system. Abnormalities in myocardial resting membrane potential, cardiac depolarization, and myocardial excitability can result in conduction system abnormalities, including malignant arrhythmias.^{1–3}

The kidneys play a central role in potassium homeostasis, with chronic kidney disease (CKD) being an especially prominent risk factor for hyperkalaemia.^{4,5} Other risk factors for hyperkalaemia commonly occur in combination with CKD, including clinical conditions such as acute kidney injury, cardiovascular disease (CVD), and diabetes mellitus (DM), and various medication classes that affect physiological processes involved in potassium regulation, such as inhibitors of the renin–angiotensin–aldosterone system (RAASi).⁶ There is wide variation in the estimates of hyperkalaemia incidence and prevalence reported in studies of CKD patients, ranging from as low as 7.7% to as high as 73%.^{7–10} Although patients in the general population are reported to have lower risk of hyperkalaemia than patients with CKD, with prevalence values ranging from 2.6% to 3.5% in Canadian and US studies, many of these studies are limited by small sample size or select populations.^{4,10,11} There are less data on hypokalaemia in general. The increasing worldwide prevalence of CKD and associated conditions compels a careful assessment of the prevalence and long-term risks associated with abnormal potassium levels in diverse international populations.^{12,13}

Hyperkalaemia and hypokalaemia have been consistently associated with higher short-term all-cause mortality in observational studies.^{8,14–18} Some, but not all, have suggested that risks associated with hyperkalaemia are greater in individuals with normal kidney function than in those with CKD.¹⁰ Notwithstanding the putative role of cardiac arrhythmias in the mortality associated with hypo- and hyperkalaemia,¹⁹ few studies have examined the long-term association of abnormal potassium levels with CVD-associated mortality. Furthermore, the effects of abnormal serum potassium levels on outcomes in other organ systems, such as the kidneys, remain less well studied. To better guide clinical practice and future clinical trials, we performed a meta-analysis of the prevalence of abnormal potassium levels, risk factors of abnormal potassium levels, and long-term associations between potassium levels, all-cause mortality, CVD-associated mortality, and end-stage renal disease (ESRD) in 27 large and diverse international cohorts. For the latter aim, we also evaluated whether risks varied by the level of kidney function and other clinically relevant characteristics.

Methods

Participating cohorts

The Chronic Kidney Disease Prognosis Consortium (CKD-PC) has been described previously; additional information is available in [Supplementary material online, Appendices S1 and S2](#).^{20–24} Briefly, CKD-PC incorporates cohorts with at least 1000 participants [at least 500 participants for those cohorts predominantly enrolling persons with CKD (CKD cohorts)], data on serum creatinine and albuminuria, and 50 or more events of the

outcome of interest (mortality or kidney outcomes). The present study included 27 cohorts: 10 general population cohorts, 7 high risk cohorts in terms of cardiovascular (CV) risk, and 10 CKD cohorts. Meta-analyses were restricted to participants aged ≥ 18 years with an available value of potassium at baseline. This study was approved by the institutional review board at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA).

Procedures

Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease–Epidemiology Collaboration (CKD–EPI) creatinine equation.²⁵ In cohorts where the creatinine measurement was not standardized to isotope dilution mass spectrometry, values were multiplied by 0.95 before eGFR calculation.²⁶ We defined diabetes as fasting glucose ≥ 7.0 mmol/L (126 mg/dL), non-fasting glucose ≥ 11.1 mmol/L (200 mg/dL), haemoglobin A1c $\geq 6.5\%$, use of glucose-lowering drugs, or self-reported diabetes. Participants with a history of myocardial infarction, coronary revascularization, heart failure, or stroke were considered to have a history of CVD. Measures of albuminuria were the urine albumin-to-creatinine ratio (ACR), urine albumin excretion rate, urine protein-to-creatinine ratio, or semi-quantitative dipstick protein; urine protein-to-creatinine ratio was converted to ACR as previously described.²⁷

The outcomes of interest were all-cause mortality, CVD-associated mortality, and ESRD. We defined ESRD as initiation of renal replacement therapy.

Statistical analysis

We applied a two-stage meta-analysis, with each study first analysed individually, followed by a random-effects meta-analysis. The overview of the analysis and analytic notes for individual studies are provided in [Supplementary material, Appendix S2](#). We imputed missing values of covariates using cohort-specific mean values. Potassium levels, serum creatinine, and albuminuria, as well as the demographic variables age, gender, and race were not imputed. We quantified heterogeneity with the I^2 statistic and Cochran's Q test. Because the risk of abnormal serum potassium levels and their associated outcomes might vary substantially depending on the type of patient population, analyses were stratified by the type of cohort (general population/high CV risk or CKD).

To assess the cross-sectional associations between kidney function and level of potassium, we plotted the distribution of baseline serum potassium levels within categories of eGFR using kernel density plots. Next, we modelled the risk of potassium >5.0 , >5.5 , and <3.5 mmol/L using logistic regression, adjusting for age, race, gender, systolic blood pressure, antihypertensive drugs, total cholesterol, diabetes mellitus, body mass index, smoking, history of coronary heart disease or stroke, history of heart failure, eGFR (linear spline with knots at 30 and 60), and albuminuria (log-transformed ACR or categories of dipstick). For eGFR and ACR, the reference point was placed at eGFR of 80 mL/min/1.73 m² and ACR of 10 mg/g in the general population/high CV risk cohorts and eGFR of 50 mL/min/1.73 m² and ACR of 50 mg/g in the CKD cohorts, with statistical significance at other points determined by the meta-analyzed beta coefficient and standard error. We tested whether the relationship between kidney function and abnormal potassium levels differed by subgroups of age, race, gender, and diabetes status, by including the relevant product term in the regression model, determining statistical significance by evaluating the ratio of odds ratios between subgroups at each 1 mL/min/1.73 m² and 8% increment of ACR (pointwise interaction), as done previously.^{20,28,29} In addition, we assessed the relationship between potassium levels >5.5 mmol/L and CKD stages (G1–G5 and A1–A3), with the reference placed as G2/A1 in the general population/high CV risk cohorts and G3b/A2 in the CKD cohorts.

To assess the relationship between baseline serum potassium and subsequent adverse outcomes, we modelled the adjusted hazard ratios (HRs) of the studied outcomes as a spline function of serum potassium concentration, fitting piecewise linear splines for serum potassium with knots placed at 3.5, 4, 4.5, 5, and 5.5 mmol/L, and adjusting for the same set of covariates. Given the importance of kidney function on potassium homeostasis, analyses were performed overall and with interaction between potassium and eGFR strata of 60+, 30–59, and <30 mL/min/1.73 m²; albuminuria levels of <30, 30–299, and ≥300 mg/g as well as age, race, gender, diabetes status, RAASi use, and diuretic use, determining statistical significance for the pointwise interaction at each 0.05 mmol/L of potassium. Analyses were performed using Stata/MP 14.2 software for Windows (www.stata.com). We considered *P*-values <0.05 as statistically significant.

Results

There were a total of 1 217 986 participants with baseline potassium, eGFR, and albuminuria levels across 27 cohorts, followed up for an average of 6.9 years (range 2.0–19). The average (mean ± standard deviation) age was 55 ± 16 years, 40% were women, and 14% were Black (Table 1). The average eGFR was 83 ± 23 mL/min/1.73 m², 17% had moderate-to-severe increased albuminuria levels, and 46% were on antihypertensive medications. Angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), and potassium-sparing diuretics were used in 31%, 11%, and 3% of individuals at baseline, respectively. Non-steroidal anti-inflammatory drugs use was reported by 15% (Supplementary material online, Table S1).

Prevalence and risk factors of hyperkalaemia and hypokalaemia

Overall, the average baseline potassium was 4.2 ± 0.4 mmol/L; potassium was higher with lower baseline eGFR in both the general population/high CV risk cohorts (Figure 1) and the CKD cohorts (Supplementary material online, Figure S1). The prevalence of serum potassium >5.0 mmol/L, serum potassium >5.5 mmol/L, serum potassium <4.0 mmol/L, and serum potassium <3.5 mmol/L was 3.31% [95% confidence interval (CI) 3.28–3.34%], 0.49% (95% CI 0.48–0.50%), 23.57% (95% CI 23.49–23.64%), and 1.91% (95% CI 1.89–1.94%) of individuals in general population/high CV risk cohorts and 17.94% (95% CI 17.58–18.31%), 4.23% (95% CI 4.03–4.42%), 12.61% (95% CI 12.29–12.93%), and 2.03% (95% CI 1.90–2.17%) of individuals in the CKD cohorts. In the general population/high CV risk cohorts, risk factors for hyperkalaemia included male gender, non-Black race, DM, lower body mass index (BMI), active smoking, history of coronary heart disease or stroke, lower eGFR, higher ACR, use of ACEi, ARB, or potassium-sparing diuretics, and non-use of thiazide or loop diuretics (Supplementary material online, Table S2). The relationship between eGFR and serum potassium >5.5 mmol/L was nearly linear; higher ACR was a weaker but an independent risk factor at levels >37 mg/g (Figure 2A and B). There were no meaningful differences in the relationship between eGFR or ACR and potassium levels >5.5 mmol/L among patients with different age (<65 years and ≥65 years), gender, race (Black and non-Black), and presence/absence of DM (Supplementary material online, Figures S2). Relationships between eGFR, ACR, and potassium >5.5 mmol/L were also similar in the CKD cohorts (Supplementary material online, Figure S6), as were the direction of associations with most risk factors (Supplementary

material online, Table S3). Categorical analysis revealed that lower eGFR was associated with higher risk of potassium level >5.5 mmol/L independent of ACR levels, whereas the association between ACR and hyperkalaemia was most apparent at higher levels of eGFR and null at eGFR <15 mL/min/1.73 m² (Supplementary material online, Table S4). Similarly, in the CKD cohorts, lower eGFR was a strong risk factor for potassium >5.5 mmol/L, whereas higher ACR was weak to null (Supplementary material online, Table S5).

Risk factors for hypokalaemia in the general population/high CV risk cohorts included younger age, female gender, Black race, higher systolic blood pressure, the use of thiazide or loop diuretics, lower serum cholesterol, lower BMI, and higher ACR; the use of ACEi, ARB, or potassium-sparing diuretics; the presence of DM; and a history of CHD or stroke were protective (Supplementary material online, Table S2). The association of higher albuminuria level with the risk of hypokalaemia was weak but nearly linear; the association between eGFR and potassium <3.5 mmol/L was fairly flat (Figure 2). Risk factor associations with potassium <3.5 mmol/L were generally consistent in direction if weaker in the CKD cohorts, with the exception of the use of RAASi medications, which was a stronger protective factor for hypokalaemia <3.5 mmol/L in the CKD cohorts (Supplementary material online, Table S3). Neither eGFR nor ACR were significantly associated with potassium <3.5 mmol/L in the CKD cohorts (Supplementary material online, Figure S6).

Outcomes associated with serum potassium level

We observed a total of 151 153 all-cause deaths in 26 cohorts, 9672 CV deaths in 13 cohorts, and 14 266 ESRD events in 16 cohorts during a mean follow-up period of 6.9 ± 4.1 years (Supplementary material online, Table S6). The risk relationship between potassium and all-cause mortality demonstrated lowest risk with serum potassium levels between 4 mmol/L and 4.5 mmol/L and higher risk outside of the 3.5–5 mmol/L range (Figure 3A). Compared with a reference of 4.2 mmol/L, the overall adjusted HR for all-cause mortality was 1.22 (95% CI 1.15–1.29) at serum potassium 5.5 mmol/L and 1.49 (95% CI 1.26–1.76) at serum potassium 3.0 mmol/L. These associations were qualitatively consistent in the individual cohorts (Figure 4), and there was no difference in the risk of all-cause mortality associated with potassium by level of eGFR (Figure 3B). Risk relationships were similarly U-shaped for CV mortality and end-stage renal disease (Figure 3C and D) with qualitative consistency in point estimates (Supplementary material online, Figures S7 and S8). Although confidence intervals were wide, there appeared to be no difference in potassium–CV risk relationships by the level of eGFR (Supplementary material online, Figure S9A). In contrast, higher levels of potassium had a weaker relationship with ESRD in individuals with eGFR <30 mL/min/1.73 m² (Supplementary material online, Figure S9B). The associations of serum potassium with the studied outcomes were broadly similar in individuals of different gender, race, levels of albuminuria, history of DM, and ACEi/ARB/potassium-sparing diuretic use; however, the association between lower levels of potassium and all-cause mortality appeared slightly weaker in older individuals and those using diuretics (Supplementary material online, Figures S10–S16). Results were also broadly similar in the CKD cohorts (Supplementary material online, Figures S17–S25).

Table 1 Baseline characteristics

Study	Region	n	Potassium (mmol/L)	eGFR, (mL/min/1.73 m ²)	Albuminuria >30 mg/g ^a	Age (years)	% Female	% Blacks	% DM	% History of CHD and/or stroke	% History of HF	% Current smoker	% HTN	SBP (mmHg)	DBP (mmHg)	BMI (kg/m ²)	Chol (mmol/L)	
General population																		
Beijing	China	1528	4.5 (0.5)	83 (14)	87 (6%)	60 (10)	772 (51%)	0 (0%)	420 (29%)	281 (18%)	—	360 (24%)	682 (45%)	125 (18)	77 (10)	25 (3)	5.3 (1.1)	
CIRCS	Japan	8034	4.2 (0.4)	89 (15)	216 (3%)	54 (9)	4990 (62%)	0 (0%)	96 (1%)	88 (1%)	—	2010 (25%)	2630 (33%)	130 (18)	79 (11)	23 (3)	5.1 (0.9)	
Gubbio	Italy	1683	4.2 (0.4)	84 (12)	70 (4%)	54 (6)	933 (55%)	0 (0%)	90 (5%)	164 (10%)	34 (2%)	524 (31%)	663 (39%)	130 (18)	78 (10)	28 (4)	5.9 (1.0)	
KHUS	South Korea	111532	4.2 (0.3)	86 (15)	4248 (4%)	46 (10)	41692 (37%)	0 (0%)	7208 (6%)	3219 (3%)	—	38734 (35%)	29159 (26%)	122 (18)	75 (12)	24 (3)	5.0 (0.9)	
MRC	UK	11840	4.4 (0.6)	57 (15)	892 (8%)	81 (5)	7221 (61%)	0 (0%)	917 (8%)	2058 (18%)	2 (100%)	1343 (11%)	4006 (34%)	149 (22)	74 (13)	26 (4)	—	
NHANES	USA	46526	4.0 (0.3)	97 (25)	5543 (12%)	47 (20)	24212 (52%)	10365 (22%)	5336 (11%)	4094 (9%)	1366 (3%)	8318 (19%)	15937 (35%)	124 (20)	71 (13)	28 (6)	5.2 (1.1)	
PREVEND	Netherlands	7319	4.4 (0.7)	96 (16)	750 (10%)	50 (13)	3768 (51%)	66 (1%)	263 (4%)	397 (5%)	19 (0%)	2440 (33%)	2443 (34%)	129 (20)	74 (10)	26 (4)	5.6 (1.1)	
Rancho Bernardo	USA	1481	4.3 (0.4)	66 (16)	217 (15%)	71 (12)	884 (60%)	1 (0%)	212 (14%)	206 (14%)	50 (3%)	115 (8%)	749 (51%)	135 (22)	76 (10)	26 (4)	5.5 (1.0)	
Taiwan Mj	Taiwan	140488	4.1 (0.3)	86 (18)	3763 (3%)	44 (15)	73278 (52%)	0 (0%)	8053 (6%)	5331 (5%)	—	24904 (26%)	29211 (21%)	122 (21)	74 (12)	23 (4)	5.0 (1.0)	
Takahata	Japan	1923	4.3 (0.4)	97 (12)	250 (13%)	64 (10)	10644 (55%)	0 (0%)	176 (9%)	131 (7%)	—	307 (16%)	1111 (58%)	134 (16)	79 (10)	23 (3)	5.2 (0.8)	
Subtotal		332354	4.1 (0.4)	87 (19)	16036 (5%)	47 (15)	158814 (48%)	10432 (19%)	22771 (7%)	15353 (5%)	1471 (3%)	79055 (28%)	86591 (26%)	124 (21)	74 (12)	24 (4)	5.1 (1.0)	
High CV risk cohorts																		
ADVANCE	Multi	11003	4.4 (0.5)	78 (17)	3400 (31%)	66 (6)	4681 (43%)	38 (0%)	11003 (100%)	3099 (28%)	352 (3%)	—	9088 (83%)	145 (21)	80 (11)	28 (5)	5.2 (1.2)	
Geisinger	USA	67023	4.3 (0.4)	80 (26)	23507 (35%)	61 (15)	34798 (52%)	1600 (2%)	43177 (64%)	17076 (25%)	5487 (8%)	9960 (15%)	50350 (75%)	131 (18)	75 (11)	33 (8)	4.8 (1.1)	
Maccabi	Israel	254379	4.4 (0.4)	86 (21)	40885 (16%)	58 (14)	125220 (49%)	0	90676 (36%)	38332 (15%)	5989 (2%)	5695 (2%)	140464 (55%)	131 (18)	78 (10)	30 (12)	4.9 (1.1)	
Mt Sinai BioMe	USA	8393	4.3 (0.6)	73 (28)	2043 (24%)	56 (14)	4810 (57%)	2773 (33%)	4244 (51%)	830 (10%)	1000 (12%)	1374 (18%)	6156 (73%)	132 (20)	77 (12)	31 (8)	4.8 (1.2)	
RCAV	USA	277226	4.3 (0.4)	77 (17)	74627 (27%)	64 (11)	9213 (3%)	45078 (16%)	218374 (79%)	93440 (34%)	18581 (7%)	—	225997 (82%)	133 (17)	75 (11)	32 (6)	4.4 (1.1)	
SCREAM	Sweden	224285	4.1 (0.4)	91 (24)	24005 (11%)	49 (17)	123720 (55%)	0	29690 (13%)	23711 (11%)	12300 (5%)	—	49250 (22%)	—	—	—	5.2 (1.1)	
ZODIAC	Netherlands	1153	4.4 (0.4)	68 (17)	92 (8%)	67 (12)	632 (55%)	0	1153 (100%)	408 (35%)	—	217 (19%)	876 (76%)	152 (24)	83 (11)	29 (5)	5.5 (1.1)	
Subtotal		843462	4.3 (0.4)	84 (22)	168559 (20%)	58 (15)	303074 (36%)	49489 (14%)	408469 (48%)	176233 (21%)	43709 (5%)	17246 (5%)	543172 (64%)	132 (18)	76 (11)	31 (9)	4.8 (1.2)	
CKD cohorts																		
AASK	USA	1081	4.2 (0.6)	46 (16)	591 (55%)	55 (11)	420 (39%)	1081 (100%)	0	535 (49%)	32 (3%)	317 (29%)	1081 (100%)	143 (22)	88 (14)	31 (7)	5.5 (1.2)	
BC CKD	Canada	11990	4.6 (0.6)	34 (17)	8660 (72%)	69 (14)	5473 (46%)	50 (0%)	7315 (61%)	3592 (30%)	1564 (13%)	635 (11%)	10149 (85%)	137 (23)	73 (13)	28 (6)	4.6 (1.3)	
CanPREDICT	Canada	2017	4.6 (0.6)	27 (9)	1487 (74%)	68 (13)	755 (37%)	32 (2%)	1010 (50%)	640 (32%)	269 (13%)	—	1973 (98%)	134 (20)	71 (12)	30 (8)	4.2 (1.2)	
CKD-JAC	Japan	2639	4.6 (0.6)	37 (17)	2335 (88%)	60 (11)	1001 (38%)	0	896 (34%)	407 (15%)	104 (4%)	385 (17%)	2472 (94%)	132 (19)	76 (12)	23 (4)	5.0 (1.1)	
CRIB	UK	373	4.6 (0.6)	22 (11)	314 (84%)	62 (14)	130 (35%)	20 (5%)	64 (17%)	93 (25%)	—	47 (13%)	350 (94%)	152 (22)	84 (12)	27 (5)	5.6 (1.3)	
MASTERPLAN	Netherlands	670	4.4 (0.6)	36 (15)	483 (72%)	60 (13)	207 (31%)	0	163 (24%)	171 (26%)	108 (17%)	138 (21%)	639 (95%)	139 (21)	80 (12)	27 (5)	4.8 (1.1)	
MDRD	USA	832	4.4 (0.6)	33 (14)	619 (74%)	52 (12)	329 (40%)	64 (8%)	82 (10%)	90 (11%)	—	81 (10%)	724 (87%)	131 (19)	80 (10)	27 (4)	5.5 (1.3)	
PSP-CKD	UK	16928	4.6 (0.5)	51 (14)	5364 (32%)	76 (11)	10138 (60%)	179 (1%)	5129 (30%)	5685 (34%)	1262 (7%)	1567 (14%)	16271 (97%)	134 (16)	74 (10)	29 (6)	4.4 (1.2)	
SRR-CKD	Sweden	2618	4.4 (0.6)	24 (11)	2061 (79%)	68 (14)	844 (32%)	0	990 (38%)	399 (15%)	379 (14%)	—	2526 (97%)	141 (23)	78 (12)	28 (5)	5.0 (1.5)	
Sunnybrook	Canada	3122	4.4 (0.5)	56 (31)	2167 (69%)	61 (18)	1443 (46%)	0	1467 (47%)	244 (8%)	217 (7%)	414 (13%)	2397 (77%)	133 (20)	76 (12)	29 (12)	4.8 (1.4)	
Subtotal		42170	4.6 (0.6)	42 (19)	24081 (57%)	70 (14)	20740 (49%)	1426 (4%)	17116 (42%)	11856 (28%)	3935 (10%)	3584 (14%)	38582 (91%)	135 (20)	75 (12)	28 (7)	4.6 (1.3)	
Total		1217986	4.2 (0.4)	83 (23)	208676 (17%)	55 (16)	482628 (40%)	61347 (14%)	448356 (37%)	203442 (17%)	49115 (5%)	99885 (16%)	668345 (55%)	129 (19)	76 (11)	29 (9)	4.9 (1.1)	

CHD, coronary heart disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HF, heart failure; HTN, hypertension; SBP, systolic blood pressure.

^aBy definition, all participants have a measure of albuminuria. Urine protein-to-creatinine ratio was converted to urine albumin-to-creatinine ratio by dividing by 2.655 for men and 1.7566 for women. Dipstick proteinuria was classified as <30 mg/g for values of negative and trace, 30–299 mg/g for 1+, and 300+ mg/g for 2+ and higher.




Figure 1 Distribution of serum potassium concentrations, overall and by baseline estimated glomerular filtration rate in the general population and high cardiovascular risk cohorts.




Figure 2 Continuous association of estimated glomerular filtration rate (A) and albuminuria (B) with the risk of serum potassium level >5.5 mmol/L and of estimated glomerular filtration rate (C) and albuminuria (D) with the risk of serum potassium level <3.5 mmol/L, in the general population and high cardiovascular risk cohorts. Black dots indicate statistical significance compared with the reference (diamond) estimated glomerular filtration rate of 80 mL/min/1.73 m² (A and C) and albuminuria of 10 mg/g (B and D). Adjusted for age, gender, race, systolic blood pressure, antihypertensive drugs, total cholesterol, diabetes, body mass index, smoking, history of coronary heart disease or stroke, and history of heart failure.

Discussion

In this international meta-analysis of 1 217 986 participants in 27 diverse cohorts, we describe the prevalence, risk factors, and long-term outcomes associated with abnormal potassium concentrations. Hyperkalaemia and hypokalaemia were relatively infrequent in the studied populations, especially in participants with normal kidney function. Lower eGFR was a strong risk factor for hyperkalaemia but

not hypokalaemia; higher albuminuria was a relatively weak risk factor for both. Both hyper- and hypokalaemia were associated with significantly higher long-term risk of all-cause and CV mortality, and of ESRD. Ideal outcomes were observed with serum potassium concentrations of 4–4.5 mmol/L. While abnormal potassium levels were more common in individuals with lower estimated GFR and higher albuminuria levels, the relative risks associated with hyperkalaemia and hypokalaemia were similar in patients with various levels of kidney




Figure 3 Adjusted hazard ratio of all-cause mortality, cardiovascular mortality, and end-stage renal disease associated with serum potassium concentration in the general population and high cardiovascular risk cohorts. Black dots indicate statistical significance compared with the reference (diamond) serum potassium of 4.2 mmol/L. Models adjusted for age, gender, race, systolic blood pressure, antihypertensive drugs, total cholesterol, diabetes, body mass index, smoking, estimated glomerular filtration rate, albuminuria, history of coronary heart disease or stroke, and history of heart failure.

function and in various subgroups divided by age, gender, race, DM, or treatment with ACEi or ARB.

Abnormal potassium homeostasis is more frequently mediated by a combination of conditions affecting potassium intake, distribution and excretion, including demographic characteristics, co-morbidities, and various medications.^{6,30} Our results confirm the diversity of the risk factors determining hyper- and hypokalaemia [including co-morbidities such as congestive heart failure (CHF) and DM,³ and therapeutic interventions such as diuretic use and RAASi³¹] and emphasize the central role played by the kidneys in potassium homeostasis. Similar to our findings, previous studies have found a low prevalence of hyperkalaemia in patients with normal kidney function and markedly elevated frequencies in various cohorts with CKD, especially in patients with DM, in those with more advanced stages of CKD^{7,8,10} and in kidney transplant recipients.⁹ As opposed to the widely accepted role of lower eGFR as a risk factor for hyperkalaemia, the role of albuminuria in engendering this condition has not been previously studied. Our results suggest that patients with higher levels of albuminuria had a higher prevalence of both hyperkalaemia and hypokalaemia, although the magnitude of this association was smaller than the relationship between eGFR and potassium abnormalities, at least for hyperkalaemia. This finding has important practical relevance, because patients with higher levels of albuminuria often benefit from therapy with RAASi medications to slow progression of CKD,³²⁻³⁷ which also increase the risk of hyperkalaemia.^{31,38,39} A secondary analysis of the Reduction of Endpoints in NIDDM with the

Angiotensin II Antagonist Losartan (RENAAL) study showed that hyperkalaemia after losartan therapy attenuated the renoprotective effect of losartan, suggesting that prevention of hyperkalaemia might allow for enhanced renoprotection by RAASi.⁴⁰ Current clinical guidelines recommend concerted efforts to resume RAASi therapy in patients with CHF, even after episodes of severe hyperkalaemia (>6 mEq/l), once hyperkalaemia was treated and precautions are taken to monitor serum potassium.³¹ Recent clinical trials suggest that the use of potassium binder medications may allow the use of RAASi in patients prone to hyperkalaemia,⁴¹⁻⁴⁵ although the long-term benefit of such strategies on clinical outcomes is yet to be demonstrated.⁴⁶

Although the prevalence of serum potassium <3.5 mmol/L was relatively low, milder forms of hypokalaemia were very common, especially in the general population/high CV risk cohorts. Even mild hypokalaemic episodes are clinically relevant in patients at high risk for ventricular arrhythmias and sudden cardiac death, such as patients with CHF or DM.^{3,31,47} Correction of hypokalaemia is relatively easy with dietary or medicinal measures,⁴⁸ and it is recommended as part of strategies to prevent these complications.³

The U-shaped association of serum potassium levels with clinical outcomes described in this study confirms the findings from previous studies, indicating similar associations with all-cause mortality,^{8,10,14-18} and extends them to an outpatient, large and diverse international population. The association between hypo- and hyperkalaemia and mortality could be explained by the induction of malignant




Figure 4 Adjusted relative hazard of all-cause mortality for potassium of 3.0 mmol/L (A) and 5.5 mmol/L (B) compared with a potassium of 4.2 mmol/L in individual general population/high cardiovascular risk cohorts.

arrhythmias^{3,19} and their consequences, such as hypotension, myocardial ischaemia, and sudden cardiac death.^{3,17} In addition, hypokalaemia and low dietary potassium intake are also associated with hypertension and consequent CV outcomes such as strokes.⁴⁸ This hypothesis is also supported by the association of hypo- and hyperkalaemia with CV mortality in our study. It is perhaps not surprising to see an association of serum potassium levels with ESRD, which has been inconsistently detected previously in smaller cohort studies.^{8,40,49,50} Hyperkalaemia that is resistant to treatment is an indication of dialysis start, and patients who require very high diuretic doses due to volume overload may have lower potassium levels and may be started earlier on dialysis. In addition to its link with hypertension, hypokalaemia is also a risk factor for tubulointerstitial fibrosis and renal cyst formation,^{51–54} thus contributing to the development and progression of CKD. Conversely, hyperkalaemia may be a surrogate marker of more severe CKD. Further studies are needed to determine whether correction of hypo- and hyperkalaemia could result in improved renal outcomes.

Our study is notable for its large size, international representation, and diverse patient population. Despite its advantages, this study also has limitations. Variation in design across cohorts introduces heterogeneity and prevents using time-updated potassium levels, but our

consistent results across diverse cohorts suggest the robust and empirical long-term association of a single measurement, relevant to clinical practice. Our results were driven largely by findings from general population cohorts, with high CV risk and CKD cohorts contributing relatively fewer participants. However, the causes and consequences of abnormal serum potassium have been least studied in the general population, hence our emphasis on this segment fills an important void. We adjusted for many confounders, but the effect of unmeasured confounders (e.g. serum calcium, magnesium, and blood pH levels) cannot be ruled out. We could not limit the studied medications (e.g. RAASi) to new prescriptions, which may explain their lack of association with outcomes.

Conclusions

The risk factors of abnormal potassium values are diverse and include low estimated GFR, albuminuria, the use of various medications and co-morbid conditions such as DM. The incorporation of these findings in clinical prediction tools in future studies could enhance our ability to risk stratify patients and to proactively manage hypo- and hyperkalaemia. Hypo- and hyperkalaemia are independently associated with significantly higher all-cause and CV mortality, and with higher risk of ESRD, with the best outcomes seen with serum potassium levels of 4–4.5 mmol/L. Future research is needed, preferably in the form of a randomized controlled clinical trial to determine whether the correction of abnormal serum potassium levels can result in improvement in mortality and delayed onset of dialysis.

Authors' contributions

C.P.K., K.M., J.C., S.H., V.S., and M.E.G. conceived of the study concept and design. K.M., J.C., M.E.G. and the CKD-PC Investigators/Collaborators listed below acquired the data. Y.S. and the Data Coordinating Center members listed below analysed the data. All authors took part in the interpretation of the data. C.P.K., K.M., Y.S., and M.E.G. drafted the manuscript, and all authors provided critical revisions of the manuscript for important intellectual content. All collaborators shared data and were given the opportunity to comment on the manuscript. J.C. obtained funding for CKD-PC and individual cohort and collaborator support is listed in [Supplementary material online, Appendix S3](#).

Supplementary material

[Supplementary material](#) is available at [European Heart Journal online](#).

Acknowledgements

CKD-PC Investigators/Collaborators (study acronyms/abbreviations provided in italics are listed in [Supplementary material online, Appendix S2](#)): AASK: Brad Astor, Larry Appel, Tom Greene, Teresa Chen; *ADVANCE*: John Chalmers, Mark Woodward, Hisatomi Arima, Vlado Perkovic; *BC CKD*: Adeera Levin, Ognjenka Djurdjev; *Beijing*: Luxia Zhang, Lisheng Liu, Minghui Zhao, Fang Wang, Jinwei Wang; *CanPREDDICT*: Adeera Levin, Ognjenka Djurdjev, Mila Tang; *CIRCS*: Hiroyasu Iso, Kazumasa Yamagishi, Mitsumasa Umehara, Isao Muraki;

CKD-JAC: Masafumi Fukagawa, Shoichi Maruyama, Takayuki Hamano, Takeshi Hasegawa, Naohiko Fujii; **CRIB:** David Wheeler, John Emberson, John Townend, Martin Landray; **Geisinger:** Jamie Green, H. Lester Kirchner, Alex R. Chang; **Gubbio:** Massimo Cirillo; **KHS:** Sun Ha Jee, Heejin Kimm, Yejin Mok; **Maccabi:** Gabriel Chodick, Varda Shalev; **MASTERPLAN:** Jack F.M. Wetzels, Peter J. Blankestijn, Arjan D. van Zuilten, M. Bots; **MDRD:** Mark Sarnak, Lesley Inker; **MRC:** Dorothea Nitsch, Paul Roderick, Astrid Fletcher; **Mt Sinai BioMe:** Erwin Bottinger, Girish N Nadkarni, Stephen B Ellis, Rajiv Nadukuru; **NHANES:** Yingying Sang; **PSP-CKD:** Nigel Brunskill, Rupert Major, David Shepherd, James Medcalf; **PREVEND:** Ron T Gansevoort, Stephan J.L. Bakker, Hiddo J. Lambers Heerspink; **Rancho Bernardo:** Simerjot K. Jassal, Jaclyn Bergstrom, Joachim H. Ix, Elizabeth Barrett-Connor; **RCAV:** Csaba Kovesdy, Kamyar Kalantar-Zadeh; **RENAAL:** Hiddo J. Lambers Heerspink, Dick de Zeeuw, Barry Brenner; **SCREAM:** Juan J. Carrero, Alessandro Gasparini, Carl-Gustaf Elinder, Peter Barany; **SRR-CKD:** Marie Evans, Mårten Segelmark, Maria Stendahl, Staffan Schön; **Sunnybrook:** Navdeep Tangri, Maneesh Sud, David Naimark; **Taiwan MJ:** Chi-Pang Wen, Chwen-Keng Tsao, Min-Kugng Tsai, Chien-Hua Chen; **Takahata:** Tsuneo Konta, Atsushi Hirayama, Kazunobu Ichikawa; **ZODIAC:** Henk J.G. Bilo, Gijs W.D. Landman, Kornelis J.J. van Hateren, Nanne Kleefstra. **CKD-PC Steering Committee:** Josef Coresh (Chair), Ron T. Gansevoort, Morgan E. Grams, Stein Hallan, Csaba P. Kovesdy, Andrew S. Levey, Kunihiro Matsushita, Varda Shalev, Mark Woodward. **CKD-PC Data Coordinating Center:** Shoshana H. Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Principal Investigator), Morgan E. Grams (Director of Nephrology Initiatives), Lucia Kwak (Programmer), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Mark Woodward (Senior Statistician). Some of the data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government.

Funding

The CKD-PC Data Coordinating Center is funded in part by a programme grant from the US National Kidney Foundation (NKF funding sources include Relypsa) and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100446-01). A variety of sources have supported enrolment and data collection including laboratory measurements and follow-up in the collaborating cohorts of the CKD-PC. These funding sources include government agencies such as national institutes of health and medical research councils as well as foundations and industry sponsors listed in [Supplementary material online, Appendix S3](#). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Conflict of interest: C.P.K. reports grants from National Institutes of Health (NIH), during the conduct of the study; personal fees from Astra Zeneca, personal fees from Relypsa, personal fees from ZS Pharma outside the submitted work. K.M. reports grants and personal fees from Kyowa Hakko Kirin outside the submitted work. N.J.B. reports grants from the UK National Institute for Health Research during the conduct of the study; grants from Baxter Healthcare outside the submitted work. J.J.C. reports grants from AstraZeneca and grants from

ViforPharma outside the submitted work. T.H. reports grants from JSPS KAKENHI and personal fees from Kyowa Hakko Kirin outside the submitted work. H.L.H. reports other support from Abbvie, grants and other support from AstraZeneca, other support from Astellas, grants and other support from Boehringer Ingelheim, grants and other support from Janssen, other support from Fresenius, and other support from Merck outside the submitted work. D.C.W. reports grants and personal fees from AstraZeneca, and personal fees from Vifor Fresenius outside the submitted work. J.C. reports grants from NIH and grants from NKF during the conduct of the study; grants from NIH and grants from NKF outside the submitted work; In addition, J.C. has a patent PCT/US2015/044567 Provisional patent [Coresh, Inker and Levey] filed 8/15/2014—precise estimation of glomerular filtration rate from multiple biomarkers issued. Y.S., G.C., A.H., G.W.D.L., A.L., D.N., S.I.H., V.S., and M.E.G. have nothing to disclose.

References

- Dittrich KL, Walls RM. Hyperkalemia: eCG manifestations and clinical considerations. *J Emerg Med* 1986;**4**:449–455.
- Parham WA, Mehdiraz AA, Biermann KM, Fredman CS. Hyperkalemia revisited. *Tex Heart Inst J* 2006;**33**:40–47.
- Priori SG, Blomstrom-Lundqvist C. 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs. *Eur Heart J* 2015; **36**:2757–2759.
- Drawz PE, Babineau DC, Rahman M. Metabolic complications in elderly adults with chronic kidney disease. *J Am Geriatr Soc* 2012;**60**:310–315.
- Bourgoignie JJ, Kaplan M, Pincus J, Gavellas G, Rabinovitch A. Renal handling of potassium in dogs with chronic renal insufficiency. *Kidney Int* 1981;**20**: 482–490.
- Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. *Nat Rev Nephrol* 2014;**10**:653–662.
- Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. *Clin J Am Soc Nephrol* 2012;**7**:1234–1241.
- Hayes J, Kalantar-Zadeh K, Lu JL, Turban S, Anderson JE, Kovesdy CP. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. *Nephron Clin Pract* 2012;**120**: c8–16.
- Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med* 2004;**351**:585–592.
- Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. *Arch Intern Med* 2009;**169**:1156–1162.
- Fleet JL, Shariff SZ, Gandhi S, Weir MA, Jain AK, Garg AX. Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. *BMJ Open* 2012;**2**:e002011.
- Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. *JAMA* 2007;**298**: 2038–2047.
- Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, Chen J, He J. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. *Kidney Int* 2015;**88**:950–957.
- Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. *Am J Kidney Dis* 1990;**15**:458–482.
- Iseki K, Uehara H, Nishime K, Tokuyama K, Yoshihara K, Kinjo K, Shiohira Y, Fukiyama K. Impact of the initial levels of laboratory variables on survival in chronic dialysis patients. *Am J Kidney Dis* 1996;**28**:541–548.
- Kovesdy CP, Regidor DL, Mehrotra R, Jing J, McAllister CJ, Greenland S, Kopple JD, Kalantar-Zadeh K. Serum and dialysate potassium concentrations and survival in hemodialysis patients. *Clin J Am Soc Nephrol* 2007;**2**:999–1007.
- Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, Kosiborod M. Serum potassium levels and mortality in acute myocardial infarction. *Jama* 2012;**307**:157–164.
- Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F, Kotanko P, Pitt B, Saran R. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. *Clin J Am Soc Nephrol* 2010;**5**:762–769.

19. Epstein FH. Signs and symptoms of electrolyte disorders. In: MH Maxwell, CR Kleeman (eds). *Clinical Disorders of Fluid and Electrolyte Metabolism*. 3rd ed. New York: McGraw-Hill; 1980. p499–516.
20. Grams ME, Sang Y, Ballew SH, Gansevoort RT, Kimm H, Kovesdy CP, Naimark D, Oien C, Smith DH, Coresh J, Sarnak MJ, Stengel B, Tonelli M, Tonelli M, Hemmelgarn BR, James MT, Turin TC, Coresh J, Matsushita K, Grams M, Sang Y, Shlipak M, Sarnak MJ, Katz R, Wheeler DC, Emberson J, Landray MJ, Townend JN, Green J, Kirchner HL, Perkins R, Chang AR, Romundstad S, Aasrød K, Øien CM, Hallan S, Smith DH, Thorp ML, Johnson ES, Chodick G, Herzel E, Katz R, Shalev V, Gansevoort RT, Bakker SJL, Lambers Heerspink HJ, van der Harst P, Jee SH, Kimm H, Mok Y, Tangri N, Naimark D, Ärnlöv J, Larsson A, Lannfelt L, Kovesdy CP, Kalantar-Zadeh K, Coresh J, Grams M, Matsushita K, Gansevoort RT, de Jong PE, Iseki K, Levey AS, Sarnak MJ, Stengel B, Warnock D, Woodward M, Ballew SH, Coresh J, Grams M, Matsushita K, Sang Y, Woodward M. A meta-analysis of the association of estimated GFR, albuminuria, age, race, and sex with acute kidney injury. *Am J Kidney Dis* 2015;**66**: 591–601.
21. Grams ME, Sang Y, Levey AS, Matsushita K, Ballew S, Chang AR, Chow EK, Kasiske BL, Kovesdy CP, Nadkarni GN, Shalev V, Segev DL, Coresh J, Lentine KL, Garg AX; for the Chronic Kidney Disease Prognosis Consortium. Kidney-failure risk projection for the living kidney-donor candidate. *N Engl J Med* 2016;**374**: 411–421.
22. Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, Chodick G, Collins AJ, Djurdjev O, Elley CR, Evans M, Garg AX, Hallan SI, Inker LA, Ito S, Jee SH, Kovesdy CP, Kronenberg F, Heerspink HJ, Marks A, Nadkarni GN, Navaneethan SD, Nelson RG, Titze S, Sarnak MJ, Stengel B, Woodward M, Iseki K. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. *JAMA* 2016;**315**:164–174.
23. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS, Prognosis Consortium CKD. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. *JAMA* 2014;**311**:2518–2531.
24. Kovesdy CP, Coresh J, Ballew SH, Woodward M, Levin A, Naimark DM, Nally J, Rothenbacher D, Stengel B, Iseki K, Matsushita K, Levey AS; the CKD Prognosis Consortium. Past decline versus current eGFR and subsequent ESRD risk. *J Am Soc Nephrol* 2016;**27**:2447–2455.
25. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;**150**:604–612.
26. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. *Clin Chem* 2007;**53**:766–772.
27. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, Itoh Y, Lieske JC, Seccombe DW, Jones G, Bunk DM, Curhan GC, Narva AS. Current issues in measurement and reporting of urinary albumin excretion. *Clin Chem* 2009;**55**:24–38.
28. James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, de Jong P, Gansevoort RT, Levey AS, Warnock DG, Sarnak MJ, Tonelli M, Hemmelgarn BR, James MT, Turin TC, Coresh J, Matsushita K, Grams M, Sang Y, Shlipak M, Sarnak MJ, Katz R, Wheeler DC, Emberson J, Landray MJ, Townend JN, Green J, Kirchner HL, Perkins R, Chang AR, Romundstad S, Aasrød K, Øien CM, Hallan S, Smith DH, Thorp ML, Johnson ES, Chodick G, Herzel E, Katz R, Shalev V, Gansevoort RT, Bakker SJL, Lambers Heerspink HJ, van der Harst P, Jee SH, Kimm H, Mok Y, Tangri N, Naimark D, Ärnlöv J, Larsson A, Lannfelt L, Kovesdy CP, Kalantar-Zadeh K, Coresh J, Grams M, Matsushita K, Gansevoort RT, de Jong PE, Iseki K, Levey AS, Sarnak MJ, Stengel B, Warnock D, Woodward M, Ballew SH, Coresh J, Grams M, Matsushita K, Sang Y, Woodward M. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. *Am J Kidney Dis* 2015;**66**:602–612.
29. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, Tonelli M, Wetzels JF, Astor BC, Gansevoort RT, Levin A, Wen CP, Coresh J. Age and association of kidney measures with mortality and end-stage renal disease. *JAMA* 2012;**308**:2349–2360.
30. Kovesdy CP. Updates in hyperkalemia: outcomes and therapeutic strategies. *Rev Endocr Metab Disord* 2017;**18**:41–47.
31. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016;**18**: 891–975.
32. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;**345**:861–869.
33. Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T; Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients Study I. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. *Hypertens Res* 2004;**27**:21–30.
34. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *N Engl J Med* 1993;**329**:1456–1462.
35. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P; the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. *N Engl J Med* 1996;**334**:939–945.
36. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). *Lancet* 1997;**349**:1857–1863.
37. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. Efficacy and safety of benazepril for advanced chronic renal insufficiency. *N Engl J Med* 2006;**354**:131–140.
38. Bozkurt B, Agostoni I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. *J Am Coll Cardiol* 2003;**41**:211–214.
39. Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. *J Am Coll Cardiol* 2005;**46**:845–849.
40. Miao Y, Dobre D, Heerspink HJ, Brenner BM, Cooper ME, Parving HH, Shahinfar S, Grobbee D, de Zeeuw D. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. *Diabetologia* 2011;**54**:44–50.
41. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ; on behalf of the PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. *Eur Heart J* 2011;**32**: 820–828.
42. Buysse JM, Huang IZ, Pitt B. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. *Future Cardiol* 2012;**8**:17–28.
43. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stavis Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; for the OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. *N Engl J Med* 2015;**372**:211–221.
44. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. *JAMA* 2014;**312**:2223–2233.
45. Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B. Sodium zirconium cyclosilicate in hyperkalemia. *N Engl J Med* 2015;**372**:222–231.
46. Kovesdy CP. Management of hyperkalemia: an update for the internist. *Am J Med* 2015;**128**:1281–1287.
47. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knutti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, De BG, Sirnes PA, Ezquerro EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck BC, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knutti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos

- C, Xuereb RG. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2013;**34**:3035–3087.
48. Kovesdy CP, Appel LJ, Grams ME, Gutekunst L, McCullough PA, Palmer BF, Pitt B, Sica DA, Townsend RR. Potassium homeostasis in health and disease: a scientific workshop cosponsored by the National Kidney Foundation and the American Society Of Hypertension. *Am J Kidney Dis* 2017;**11**:783–800.
49. Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV, Jr, Navaneethan SD. Serum potassium, end-stage renal disease and mortality in chronic kidney disease. *Am J Nephrol* 2015;**41**:456–463.
50. Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. *Eur J Prev Cardiol* 2014;**21**:299–309.
51. Cremer W, Bock KD. Symptoms and course of chronic hypokalemic nephropathy in man. *Clin Nephrol* 1977;**7**:112–119.
52. Elger M, Bankir L, Kriz W. Morphometric analysis of kidney hypertrophy in rats after chronic potassium depletion. *Am J Physiol* 1992;**262**:F656–F667.
53. Riemenschneider T, Bohle A. Morphologic aspects of low-potassium and low-sodium nephropathy. *Clin Nephrol* 1983;**19**:271–279.
54. Torres VE, Young WF Jr., Offord KP, Hattery RR. Association of hypokalemia, aldosteronism, and renal cysts. *N Engl J Med* 1990;**322**:345–351.